Skip to main content

Table 2 List of outcome categories/outcomes in COS from the included studies by study type

From: A scoping review of core outcome sets and their ‘mapping’ onto real-world data using prostate cancer as a case study

Outcome classification/Outcomes All COS studies (n = 11); COS for clinical trials or clinical research (n = 8) COS for practice (n = 2) COS/patient reported outcomes (n = 1)
No. O No. S No. O No. S No. O No. S No. O No. S
Mortality and survival 18 8 15 6 3 2 NA NA
 Survival 2   2   0   NA  
 Overall survival 5   3   2   NA  
 Cause- (or disease) specific survival 6   5   1   NA  
 Relative survival 1   1   0   NA  
 Metastasis-free survival 2   2   0   NA  
 Progression-free survival 1   1   0   NA  
 Biochemical recurrence-free survival 1   1   0   NA  
Outcomes relating to neoplasms 19 7 18 6 1 1 0 0
  (Change in) prostate-specific antigen (PSA) levels 3   3   0   0  
 Measurable disease response 1   1   0   0  
 Time to progression 2   2   0   0  
 Disease progression/Progression rate 2   2   0   0  
 Progression-free probability 1   1   0   0  
 Development of metastases 1   1   0   0  
 Metastases-free probability 1   1   0   0  
 Symptomatic skeletal event 1   0   1   0  
 Local disease 1   1   0   0  
 Positive surgical margins 1   1   0   0  
 Response duration 1   1   0   0  
 Failure-free probability 1   1   0   0  
 Development of castration-resistant disease 1   1   0   0  
 Treatment failure 2   2   0   0  
Renal and urinary outcomes 13 6 8 3 3 2 2 1
 Urinary incontinence 4   2   1   1  
 Urinary obstruction/irritation 3   1   1   1  
 Urinary symptoms 1   0   1   0  
 Voiding behaviour 1   1   0   0  
 Haematuria 1   1   0   0  
 Pelvic pain 1   1   0   0  
 Lymphedema 1   1   0   0  
 Urinary functioning 1   1   0   0  
Gastrointestinal outcomes 6 5 3 2 2 2 1 1
 Bowel symptoms 3   0   2   1  
 Faecal incontinence 1   1   0   0  
 Bowel functioning 1   1   0   0  
 Diarrhoea 1   1   0   0  
Endocrine outcomes 3 3 0 0 2 2 1 1
 Hormonal symptoms 3   0   2   1  
Reproductive system outcomes 6 6 3 3 2 2 1 1
 Erectile/sexual function 2   2   0   0  
 Erectile/sexual dysfunction (impotence) 3   1   1   1  
 Sexual symptoms 1   0   1   0  
General outcomes 8 3 3 1 3 1 2 1
 Pain 2   0   1   1  
 Fatigue 2   0   1   1  
 Bone pain 1   1   0   0  
 Weight loss 1   1   0   0  
 Anaemia 1   1   0   0  
 Performance status 1   0   1   0  
Physical functioning 3 3 1 1 1 1 1 1
 Physical wellbeing/functioning 3   1   1   1  
Emotional functioning/wellbeing 4 4 2 2 1 1 1 1
 Mental/emotional wellbeing/functioning 4   2   1   1  
Social functioning 1 1 1 1 0 0 0 0
 Social functioning 1   1   0   0  
Role functioning 1 1 1 1 0 0 0 0
 Role functioning 1   1   0   0  
Global quality of life 6 6 6 6 0 0 0 0
 Quality of life 6   6   0   0  
Economic outcomes 2 2 2 2 0 0 0 0
 Cost-effectiveness 1   1   0   0  
 Costs 1   1   0   0  
Need for intervention 4 2 2 1 2 1 0 0
 Need for salvage therapy 1   1   0   0  
 Need for curative treatment 1   1   0   0  
 Need for pain medication 1   0   1   0  
 Procedures need for local progression 1   0   1   0  
Delivery of care 1 1 1 1 0 0 0 0
 Time to treatment failure 1   1   0   0  
Adverse events/effects 8 6 6 4 2 2 0 0
 Adverse events 3   2   1   0  
 Perioperative deaths 1   1   0   0  
 Thromboembolic disease 1   1   0   0  
 Bothersome or symptomatic urethral or anastomotic stricture 1   1   0   0  
 Side-effects of hormonal therapy 1   1   0   0  
 Major systemic therapy effects 1   0   1   0  
Total 103   72   22   9  
  1. NA Not applicable,